Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK4 | O96013 | 2/20 | 0.63 |
| ▸ | NAMPT | P43490 | 2/20 | 0.63 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.63 |
| ▸ | LIPC | P11150 | 4/20 | 0.35 |
| ▸ | GPR183 | P32249 | 4/20 | 0.35 |
| ▸ | ERN1 | O75460 | 1/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | PKLR | P30613 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17859411 | 0.96 | PAK4 (0.58) | PAK4NAMPTPAK1LIPCGPR183 | |
| SCHEMBL17859221 | 0.93 | PAK4 (0.55) | PAK4NAMPTPAK1LIPCGPR183 | |
| SCHEMBL17859409 | 0.93 | PAK4 (0.55) | PAK4NAMPTPAK1LIPCGPR183 | |
| SCHEMBL17859420 | 0.93 | PAK4 (0.54) | PAK4NAMPTPAK1LIPCGPR183 | |
| SCHEMBL17859535 | 0.93 | PAK4 (0.63) | PAK4NAMPTPAK1LIPCGPR183 | |
| SCHEMBL17859222 | 0.92 | PAK4 (0.54) | PAK4NAMPTPAK1LIPCGPR183 | |
| SCHEMBL17859412 | 0.91 | PAK4 (0.52) | PAK4NAMPTPAK1LIPCGPR183 | |
| SCHEMBL17859256 | 0.91 | NAMPT (0.52) | PAK4NAMPTPAK1GPR183ERN1 | |
| SCHEMBL17859374 | 0.89 | PAK4 (0.59) | PAK4NAMPTPAK1LIPCGPR183 | |
| SCHEMBL17859239 | 0.88 | PAK4 (0.59) | PAK4NAMPTPAK1LIPCGPR183 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170369470-A1 | Cyclic Compounds and Uses Thereof | Karyopharm Therapeutics Inc. | 2017-12-28 | — | — | US | disclosed |
| WO-2016100515-A1 | CYCLIC COMPOUNDS AND USES THEREOF | Karyopharm Therapeutics Inc. (US) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170369470-A1 | Cyclic Compounds and Uses Thereof | MALT1, BCL9, BCL6 | PAK4 1077/4885NAMPT 1646/4885PAK1 1131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.